Plasmid-mediated quinolone resistance - Current knowledge and future perspectives

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 20-30

  Guan, Xizhou ^a   Xue, Xinying ^b   Liu, Yuxia ^c   Wang, Jing ^b   Wang, Yong ^b   Wang, Jianxin ^a   Wang, Kaifei ^a   Jiang, Hong ^b   Zhang, Lina ^a   Yang, Bing ^a   Wang, N ^a   Pan, Lei ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Drug resistance; Fluoroquinolone; Plasmid mediated quinolone resistance; Qnr; Quinolone

Indexed keywords

ALANINE; ASPARTIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GEMIFLOXACIN; GLUTAMIC ACID; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AEROBIC BACTERIUM; AMINO ACID SUBSTITUTION; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CELL MEMBRANE PERMEABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL INFECTION; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE TRANSFER; GENETIC VARIABILITY; GEOGRAPHIC ORIGIN; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYRA GENE; GYRB GENE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PLASMID; PLASMID MEDIATED ANTIBIOTIC RESISTANCE; POINT MUTATION; QNR GENE; QNRA GENE; QNRA1 GENE; QNRB GENE; QNRB1 GENE; QNRB12 GENE; QNRB2 GENE; QNRS GENE; RESPIRATORY TRACT INFECTION; REVIEW; SEQUENCE HOMOLOGY;

EID: 84878421301     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513475965     Document Type: Review

References (76)

1. Lesher GY, Froelich EJ, Gruett MD, et al. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 91: 1063-1065.
2. Domagala JM, Hagen SE, Heifetz CL, et al. 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. J Med Chem 1988; 31: 503-506.
3. Hooper DC and Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985; 28: 716-721.
4. Brighty KE, Gootz TD: Chapter 2-Chemistry and Mechanism of Action of the Quinolone Antibacterials. In: The Quinolones, 3rd edn (Andriole VT, ed). San Diego: Academic Press, 2000; pp 33-97.
5. Moellering RC Jr. The fluoroquinolones: the last Samurai? Clin Infect Dis 2005; 41(suppl 2): S111-S112.
6. Hoellman DB, Kelly LM, Jacobs MR, et al. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001; 45: 589-592.
7. Ameyama S, Shinmura Y and Takahata M. Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003; 47: 2327-2329.
8. Noviello S, Ianniello F, Leone S, et al. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 2003; 52: 869-872.
9. Drlica K and Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392.
10. Li XZ. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 2005; 25: 453-463.
11. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003; 51(suppl 1): 29-35.
12. Khodursky AB and Cozzarelli NR. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 1998; 273: 27668-27677.
13. Nicolle LE: Chapter 6-Use of Quinolones in Urinary Tract Infection and Prostatitis. In: The Quinolones, 3rd edn (Andriole VT, ed). San Diego: Academic Press, 2000; pp 203-225.
14. Akalin EH. Quinolones in the treatment of typhoid fever. Drugs 1999; 58(suppl 2): 52-54.
15. Oliphant CM and Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-464.
16. Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002; 347: 1770-1782.
17. Ridha AG, Malbrain ML, Mareels J, et al. Lung abscess due to nontyphoid Salmonella in an immunocompromised host. Case report with review of the literature. Acta Clin Belg 1996; 51: 175-183.
18. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2: 38-55.
19. Jacoby GA, Walsh KE, Mills DM, et al. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother 2006; 50: 1178-1182.
20. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gramnegative bacilli in US intensive care units. JAMA 2003; 289: 885-888.
21. Oteo J, Aracil B, Hoyo JF, et al. Do the quinolones still constitute valid empirical therapy for community-acquired urinary tract infections in Spain? Clin Microbiol Infect 1999; 5: 654-656.
22. Wang H, Dzink-Fox JL, Chen M, et al. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001; 45: 1515-1521.
23. Kariuki S, Revathi G, Muyodi J, et al. Characterization of multidrug-resistant typhoid outbreaks in Kenya. J Clin Microbiol 2004; 42: 1477-1482.
24. Nath G, Tikoo A, Manocha H, et al. Drug resistance in Salmonella typhi in North India with special reference to ciprofloxacin. J Antimicrob Chemother 2000; 46: 149-150.
25. Parry C, Wain J, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351: 1289.
26. Hakanen A, Kotilainen P, Huovinen P, et al. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 2001; 7: 996-1003.
27. Mølbak K, Gerner-Smidt P and Wegener HC. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg Infect Dis 2002; 8: 514-515.
28. Bakken JS. The fluoroquinolones: how long will their utility last? Scand J Infect Dis 2004; 36: 85-92.
29. NORM/NORM-VET Report 2006: Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway (available at: http://www.vetinst.no/eng/ Publications/Norm-Norm-Vet-Report).
30. Normark BH and Normark S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252: 91-106.
31. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999; 58(suppl 2): 11-18.
32. Friedman SM, Lu T and Drlica K. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 2001; 45: 2378-2380.
33. Eaves DJ, Liebana E, Woodward MJ, et al. Detection of gyrA mutations in quinoloneresistant Salmonella enterica by denaturing high-performance liquid chromatography. J Clin Microbiol 2002; 40: 4121-4125.
34. Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-831.
35. Ling JM, Chan EW, Lam AW, et al. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong. Antimicrob Agents Chemother 2003; 47: 3567-3573.
36. Giraud E, Cloeckaert A, Kerboeuf D, et al. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000; 44: 1223-1228.
37. Toro CS, Lobos SR, Calderón I, et al. Clinical isolate of a porinless Salmonella typhi resistant to high levels of chloramphenicol. Antimicrob Agents Chemother 1990; 34: 1715-1719.
38. Piddock LJ, Griggs DJ, Hall MC, et al. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother 1993; 37: 662-666.
39. Ruiz J, Castro D, Goñi P, et al. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. J Med Microbiol 1997; 46: 623-628.
40. Martínez JL, Alonso A, Gómez-Gómez JM, et al. Quinolone resistance by mutations in chromosomal gyrase genes Just the tip of the iceberg? J Antimicrob Chemother 1998; 42: 683-688.
41. Jacoby G, Cattoir V, Hooper D, et al. qnr Gene nomenclature. Antimicrob Agents Chemother 2008; 52: 2297-2299.
42. Strahilevitz J, Jacoby GA, Hooper DC, et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664-689.
43. Tran JH, Jacoby GA and Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005; 49: 118-125.
44. Hata M, Suzuki M, Matsumoto M, et al. Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimicrob Agents Chemother 2005; 49: 801-803.
45. Nordmann P and Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56: 463-469.
46. Robicsek A, Jacoby GA and Hooper DC. The worldwide emergence of plasmidmediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-640.
47. Gay K, Robicsek A, Strahilevitz J, et al. Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis 2006; 43: 297-304.
48. Kehrenberg C, Hopkins KL, Threlfall EJ, et al. Complete nucleotide sequence of a small qnrS1-carrying plasmid from Salmonella enterica subsp. enterica Typhimurium DT193. J Antimicrob Chemother 2007; 60: 903-905.
49. Touati A, Brasme L, Benallaoua S, et al. First report of qnrB-producing Enterobacter cloacae and qnrA-producing Acinetobacter baumannii recovered from Algerian hospitals. Diagn Microbiol Infect Dis 2008; 60: 287-290.
50. Wang M, Tran JH, Jacoby GA, et al. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 2003; 47: 2242-2248.
51. Mammeri H, Van De Loo M, Poirel L, et al. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49: 71-76.
52. Jeong J-Y, Yoon HJ, Kim ES, et al. Detection of qnr in clinical isolates of Escherichia coli from Korea. Antimicrob Agents Chemother 2005; 49: 2522-2524.
53. Nazic H, Poirel L and Nordmann P. Further identification of plasmid-mediated quinolone resistance determinant in Enterobacteriaceae in Turkey. Antimicrob Agents Chemother 2005; 49: 2146-2147.
54. Cambau E, Lascols C, Sougakoff W, et al. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect 2006; 12: 1013-1020.
55. Poirel L, Leviandier C and Nordmann P. Prevalence and genetic analysis of plasmidmediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital. Antimicrob Agents Chemother 2006; 50: 3992-3997.
56. Park CH, Robicsek A, Jacoby GA, et al. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 3953-3955.
57. Rodríguez-Martínez JM, Velasco C, Pascual A, et al. Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three qnrA-containing plasmids. Clin Microbiol Infect 2006; 12: 440-445.
58. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-88.
59. Poirel L, Rodriguez-Martinez JM, Mammeri H, et al. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother 2005; 49: 3523-3525.
60. Cattoir V, Poirel L and Nordmann P. Plasmid-mediated quinolone resistance determinant QnrB4 in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. Antimicrob Agents Chemother 2007; 51: 2652-2653.
61. Tran JH and Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99: 5638-5642.
62. Wang M, Sahm DF, Jacoby GA, et al. Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 2004; 48: 1400-1401.
63. Corkill JE, Anson JJ and Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. J Antimicrob Chemother 2005; 56: 1115-1117.
64. Robicsek A, Strahilevitz J, Sahm DF, et al. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006; 50: 2872-2874.
65. Chen YT, Shu HY, Li LH, et al. Complete nucleotide sequence of pK245, a 98-kilobase plasmid conferring quinolone resistance and extended-spectrum-β-lactamase activity in a clinical Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2006; 50: 3861-3866.
66. Kehrenberg C, Friederichs S, de Jong A, et al. Identification of the plasmid-borne quinolone resistance gene qnrS in Salmonella enterica serovar Infantis. J Antimicrob Chemother 2006; 58: 18-22.
67. Hu FP, Xu XG, Zhu DM, et al. Coexistence of qnrB4 and qnrS1 in a clinical strain of Klebsiella pneumoniae. Acta Pharmacol Sin 2008; 29: 320-324.
68. Pai H, Seo MR and Choi TY. Association of QnrB determinants and production of extended-spectrum β-lactamases or plasmidmediated AmpC β-lactamases in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 2007; 51: 366-368.
69. Cavaco LM, Hendriksen RS and Aarestrup FM. Plasmid-mediated quinolone resistance determinant qnrS1 detected in Salmonella enterica serovar Corvallis strains isolated in Denmark and Thailand. J Antimicrob Chemother 2007; 60: 704-706.
70. Avsaroglu MD, Helmuth R, Junker E, et al. Plasmid-mediated quinolone resistance conferred by qnrS1 in Salmonella enterica serovar Virchow isolated from Turkish food of avian origin. J Antimicrob Chemother 2007; 60: 1146-1150.
71. Lavilla S, González-López JJ, Sabaté M, et al. Prevalence of qnr genes among extended-spectrum β-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother 2008; 61: 291-295.
72. Poirel L, Cattoir V, Soares A, et al. Novel Ambler class A β-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. Antimicrob Agents Chemother 2007; 51: 631-637.
73. Bönemann G, Stiens M, Pühler A, et al. Mobilizable IncQ-related plasmid carrying a new quinolone resistance gene, qnrS2, isolated from the bacterial community of a wastewater treatment plant. Antimicrob Agents Chemother 2006; 50: 3075-3080.
74. Kehrenberg C, Friederichs S, de Jong A, et al. Novel variant of the qnrB gene, qnrB12, in Citrobacter werkmanii. Antimicrob Agents Chemother 2008; 52: 1206-1207.
75. Garnier F, Raked N, Gassama A, et al. Genetic environment of quinolone resistance gene qnrB2 in a complex sul1-type integron in the newly described Salmonella enterica serovar Keurmassar. Antimicrob Agents Chemother 2006; 50: 3200-3202.
76. Herrera-León S, González-Sanz R, Herrera-León L, et al. Characterization of multidrugresistant Enterobacteriaceae carrying plasmid-mediated quinolone resistance mechanisms in Spain. J Antimicrob Chemother 2011; 66: 287-290.